Allogene Therapeutics Q3 2026 Results: Net Loss of $50.4M, Loss Widens
Allogene Therapeutics reported a net loss of $50.4 million for the third quarter of 2026, an increase from the $41.4 million loss in the same period of 2025. The company strengthened its balance sheet through a public offering and ATM sales, ending the period with $392.6 million in total stockholders' equity compared to $292.5 million at the end of 2025.
- Key figure
- Net loss $50.4M